The North America pharma cloud services market, valued at USD 5.7 billion in 2025, is projected to reach USD 6.8 billion in 2026 and USD 21.2 billion by 2035, representing a CAGR of 13.5% during the forecast period from 2026 to 2035. Pharmaceutical companies in North America are increasingly adopting AI-enabled cloud platforms to accelerate drug discovery, clinical development, regulatory documentation, manufacturing, and commercial operations. As pharma companies handle large volumes of genomic...

The global ulcerative colitis market size, valued at USD 13.0 billion in 2025, is projected to reach USD 14.0 billion in 2026 and USD 25.7 billion by 2035, representing a CAGR of 7.0% during the forecast period 2026 to 2035. Based on route of administration, the subcutaneous route dominates (more than 40%) the current market; this trend is unlikely to change in the future. With respect to distribution channels, hospital pharmacies are expected to capture most of the future ulcerative colitis mar...

The global Crohn’s disease market size, valued at USD 9.6 billion in 2025, is projected to reach USD 10.3 billion in 2026 and USD 18.1 billion by 2035, representing a CAGR of 6.5% during the forecast period 2026 to 2035. Based on the route of administration, the subcutaneous route dominates (more than 40%) the future market (2035). The rising prevalence of Crohn’s disease represents a major market opportunity within this domain. Notably, in 2023, an estimated 1 million patients were living w...

The global RNAi therapeutics market, valued at USD 2.9 billion in 2025, is projected to reach USD 3.6 billion in 2026 and USD 9.1 billion by 2035, representing a CAGR of 10.8% during the forecast period 2026 to 2035. With respect to route of administration, intravenous administration accounts for the highest share, capturing 45% of the current market. In June 2026, Alnylam Pharmaceuticals and Inceptive Nucleics announced a strategic AI-driven collaboration valued at up to USD 2 billion, includin...

The global bacteriophage therapy market, valued at USD 58.1 million in 2025, is projected to reach USD 66.5 million in 2026 and USD 266.8 million by 2035, representing a CAGR of 16.7% during the forecast period 2026 to 2035. In terms of target indication, urinary tract infections hold the highest (around 30%) share of the current market. With respect to route of administration, oral route dominates the current market.

The global healthcare interoperability solutions market is expected to rise from USD 5.8 billion in 2026 to reach USD 31.5 billion by 2040, growing at a CAGR of 12.8% over the forecast period 2026 to 2040, driven by regulatory interoperability mandates and cloud-native FHIR adoption. Long-term growth will accelerate as cloud deployment, semantic interoperability, and FHIR APIs reshape procurement through 2040. Oracle Health received TEFCA QHIN designation in November 2025 and linked customer onb...

The global idiopathic short stature market is expected to rise from USD 1.85 billion in 2026 to reach USD 5.08 billion by 2040, growing at a CAGR of 7.48% over the forecast period 2026 to 2040, driven by weekly growth hormone adoption, home-based treatment, and genetic reclassification of short stature. Based on Geography, North America captures 45.0% market share in 2026, whereas Asia-Pacific registers a 10.2% CAGR through 2040, driven by faster private endocrine care expansion. Based on Therap...

The North America non-viral transfection reagents market, valued at USD 0.31 billion in 2025, is projected to reach USD 0.34 billion in 2026 and USD 0.70 billion by 2035, representing a CAGR of 8.5% during the forecast period 2026 to 2035. Non-viral transfection reagents have become integral to modern molecular biology and therapeutic development, offering reliable and scalable alternatives to viral vectors for delivering nucleic acids into cells. The chemical and physical transfection approache...

The global Duchenne muscular dystrophy market reached USD 5.2 billion in 2026 and is projected to reach USD 28.7 billion by 2040, growing at a CAGR of 13.0% over the forecast period 2026 to 2040, driven by mutation-targeted therapies, gene transfer adoption, and broader rare-disease reimbursement. Based on therapy class, gene therapies capture 34.0% market share in 2026, whereas cell therapies register a 28.4% CAGR through 2040, driven by late-stage cardiac and skeletal-muscle programs. Based on...

The global eConsent in healthcare market is expected to rise from USD 0.62 billion in 2026 and is projected to reach USD 2.48 billion by 2040, growing at a CAGR of 10.4% over the forecast period 2026 to 2040, driven by clinical-trial digitalization, remote consent workflows, and regulated patient-data sharing. Based on platform / deployment model, cloud-based platforms capture 70.0% market share in 2026, whereas hybrid deployments register an 18.8% CAGR through 2040, driven by mixed site-and-rem...

The Europe cancer metabolism based therapeutics market, valued at USD 0.82 billion in 2025, is projected to reach USD 1.12 billion in 2026 and USD 8.54 billion by 2035, with a CAGR of 25.3% during the forecast period 2026 to 2035. In terms of type of modality, small molecules are expected to account for the largest market share in 2026; this trend is unlikely to change in the future. With respect to route of administration, oral route (close to 85%) is expected to dominate the market in 2035. Th...

The global large volume wearable injectors market, valued at USD 12.6 billion in 2025, is projected to reach USD 16.4 billion in 2026 and USD 31.4 billion by 2035, representing a CAGR of 7.5% during the forecast period 2026 to 2035. The market numbers have been calculated by taking into account the revenues generated through sales of large volume wearable injectors and related drug-device combination products. Based on market share distribution by therapeutic area, devices used to treat autoimmu...

The global AI-powered pharmacovigilance market is expected to rise from USD 0.83 billion in 2026 and is projected to reach USD 5.59 billion by 2040, growing at a CAGR of 14.6% over the forecast period 2026 to 2040, driven by rising safety-data complexity. Based on deployment model, cloud-based solutions are both dominant and fastest-growing, holding 58.0% share in 2026 and expanding at 16.1% CAGR through 2040, driven by scalable global safety operations.

The global automated rapid microbiology testing platforms market, valued at USD 48.7 million in 2025, is projected to reach USD 51.7 million in 2026 and USD 108.7 million by 2035, representing a CAGR of 8.6% during the forecast period 2026 to 2035. In terms of type of modality, biologics accounts for the highest share (over 60%) of the current market. With respect to type of offering, consumables dominate the current market.

The global PERK inhibitors market is envisaged to rise from USD 46.0 million in 2026 and is projected to reach USD 450.0 million by 2040, growing at a CAGR of 17.7% over the forecast period 2026 to 2040, driven by Phase 1b oncology combination development and research-enablement demand. Based on product / offering type, therapeutic drug candidates is both the dominant and fastest-growing category, holding 34.0% share in 2026 and expanding at 21.3% CAGR through 2040, driven by oncology pipeline v...

The global digital phenotyping market is expected to rise from USD 2.0 billion in 2026 and is projected to reach USD 7.1 billion by 2040, growing at a CAGR of 9.5% over the forecast period 2026 to 2040, driven by regulated remote digital endpoints and AI-enabled multimodal capacity monitoring. Based on Geography, North America captures 42.0% market share in 2026, whereas Asia-Pacific registers a 12.4% CAGR through 2040, driven by healthcare digitalization and trial localization.

The Europe non-viral transfection reagents market, valued at USD 0.22 billion in 2025, is projected to reach USD 0.24 billion in 2026 and USD 0.40 billion by 2035, representing a CAGR of 5.7% during the forecast period 2026-2035. Non-viral transfection reagents refer to chemical or physical delivery systems that introduce nucleic acids, including DNA, RNA, mRNA, siRNA, and gene editing components, into target cells without relying on viral vectors. In addition, rising investment in nucleic acid-...

The global CRISPR based therapeutics market, valued at USD 0.1 billion in 2025, is projected to reach USD 0.2 billion in 2026 and USD 6.3 billion by 2035, with a CAGR of 43.8% during the forecast period 2026 to 2035. The CRISPR domain has evolved from basic scientific research into an important area of advanced therapeutics. Notably, the in vivo therapies segment is expected to grow at a significant pace during the forecast period due to rapid advancements in targeted gene-editing delivery techn...

The global cloud based drug discovery platforms market, valued at USD 3.7 billion in 2025, is projected to reach USD 4.2 billion in 2026 and USD 11.4 billion by 2035, representing a CAGR of 11.7% during the forecast period 2026 to 2035. Cloud based drug discovery platforms are centralized, internet-hosted software ecosystems that provide scalable computing power, data storage, and advanced analytics tools to accelerate the discovery of new therapeutic compounds. According to our projections, Nor...

The global hospital command center market is expected to rise from USD 2.40 billion in 2026 to reach USD 10.10 billion by 2040, growing at a CAGR of 10.8% over the forecast period 2026 to 2040, driven by hospital-wide demand for real-time capacity orchestration. Based on Geography, North America captures 42.0% market share in 2026, whereas Asia-Pacific registers a 13.5% CAGR through 2040, supported by digital hospital infrastructure expansion.